Ichthyosis is scaling and flaking of skin ranging from mild but annoying dryness to severe disfiguring disease. Ichthyosis can also be a sign of systemic disease. Diagnosis is clinical. Treatment involves emollients and sometimes oral retinoids.
Ichthyosis differs from simple dry skin (xeroderma—see Cornification Disorders: Xeroderma) by its association with a systemic disorder or drug, inheritability, severity, or a combination. Ichthyosis can also be much more severe than xeroderma.
Inherited ichthyoses, which are characterized by excessive accumulation of scale on the skin surface, are classified according to clinical and genetic criteria (see Table 1: Cornification Disorders: Clinical and Genetic Features of Some Inherited Ichthyoses). Some occur in isolation and are not part of a syndrome (eg, ichthyosis vulgaris, X-linked ichthyosis, lamellar ichthyosis, epidermolytic hyperkeratosis [bullous congenital ichthyosiform erythroderma]). Other ichthyoses are part of a syndrome that involves multiple organs. For instance, Refsum disease (see Inherited Disorders of Metabolism: Classic Refsum's disease) and Sjögren-Larsson syndrome (hereditary intellectual disability and spastic paralysis caused by a defect in fatty aldehyde dehydrogenase) are autosomal recessive conditions with skin and extracutaneous organ involvement. A dermatologist should assist in diagnosis and management, and a medical geneticist should be consulted for genetic counseling.
Ichthyosis may be an early manifestation of some systemic disorders (eg, leprosy, hypothyroidism, lymphoma, AIDS). Some drugs cause ichthyosis (eg, nicotinic acid, triparanol, butyrophenones). The dry scale may be fine and localized to the trunk and legs, or it may be thick and widespread. Biopsy of ichthyotic skin is usually not diagnostic of the systemic disorder; however, there are exceptions, most notably sarcoidosis, in which a thick scale may appear on the legs, and biopsy usually shows the typical granulomas.
When ichthyosis is caused by a systemic disorder, the underlying disorder must be treated for the ichthyosis to abate. Other treatments include emollients and keratolytics and avoiding drying.
Moisturization and keratolytics:
In any ichthyosis, there is impaired epidermal barrier function, and moisturizers should be applied immediately after bathing. Substances that are applied to the skin may have increased absorption. For example, hexachlorophene products should not be used because of increased absorption and toxicity.
An emollient, preferably plain petrolatum, mineral oil, or lotions containing urea or α-hydroxy acids (eg, lactic, glycolic, and pyruvic acids), should be applied twice daily, especially after bathing while the skin is still wet. Blotting with a towel removes excess applied material.
Ichthyosis typically responds well to the topical keratolytic propylene glycol. To remove scale (eg, if ichthyosis is severe), patients can apply a preparation containing 40 to 60% propylene glycol in water under occlusion (eg, a thin plastic film or bag worn overnight) every night after hydrating the skin (eg, by bathing or showering); in children, the preparation should be applied twice daily without occlusion. After scale has decreased, less frequent application is required. Other useful topical agents include ceramide-based creams, 6% salicylic acid gel, hydrophilic petrolatum and water (in equal parts), and the α-hydroxy acids in various bases. Topical calcipotriol cream has been used with success; however, this vitamin D derivative can result in hypercalcemia when used over broad areas, especially in small children.
Retinoids are effective in treating inherited ichthyosis. Oral synthetic retinoids are effective for most ichthyoses. Acitretin (see Psoriasis and Scaling Diseases: Systemic treatments) is effective in treating most forms of inherited ichthyosis. In lamellar ichthyosis, 0.1% tretinoin cream or oral isotretinoin may be effective. The lowest effective dose should be used. Long-term (1 yr) treatment with oral isotretinoin has resulted in bony exostoses in some patients, and other long-term adverse effects may arise.
Patients with epidermolytic hyperkeratosis may need long-term treatment with cloxacillin 250 mg po tid or qid or erythromycin 250 mg po tid or qid, as long as thick intertriginous scale is present, to prevent bacterial superinfection from causing painful, foul-smelling pustules. Regularly using soaps containing chlorhexidine may also reduce the bacteria, but these soaps tend to dry the skin.
Last full review/revision March 2013 by James G. H. Dinulos, MD
Content last modified April 2013